MARKET

XLRN

XLRN

Acceleron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

127.79
-0.11
-0.09%
After Hours: 127.79 0 0.00% 16:42 03/05 EST
OPEN
127.06
PREV CLOSE
127.90
HIGH
128.58
LOW
119.20
VOLUME
987.20K
TURNOVER
--
52 WEEK HIGH
144.26
52 WEEK LOW
66.44
MARKET CAP
7.74B
P/E (TTM)
-43.9579
1D
5D
1M
3M
1Y
5Y
Imara Reports Full Year 2020 Financial Results and Business Highlights
GlobeNewswire · 2d ago
Autolus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
LONDON, March 04, Mar 04, 2021 (GLOBE NEWSWIRE via COMTEX) -- LONDON, March 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a...
GlobeNewswire · 3d ago
Thalassemia Market Set to Witness Growth 2021, Emerging industries, Challenges and Threats Faced by Key Vendors, Development Trends, Share, Size, Demand and 2026 Forecast Research Report
Mar 04, 2021 (The Expresswire) -- The Thalassemia industry has undergone many changes in recent years and expects numerous variations in the coming year due...
The Express Wire · 3d ago
Global Transforming Growth Factor Beta 1 Market 2020 Industrial Chain, Regional Market Scope, Key Players Profiles and Sales Data to 2025
Mar 03, 2021 (CDN Newswire via Comtex) -- Global Transforming Growth Factor Beta 1 Market 2020 by Manufacturers, Regions, Type and Application, Forecast to...
CDN Newswire · 3d ago
The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 1)
Benzinga · 5d ago
Transforming Growth Factor Beta 1 Market 2020 Business Strategies, Production and Comprehensive Research Study till 2025
Mar 02, 2021 (Heraldkeepers) -- The global Transforming Growth Factor Beta 1 market report provides geographic analysis covering regions, such as North...
Heraldkeepers · 5d ago
Anemia Drugs Market Demand Fuelled by Increased R and D Activities, Says Market.us
Mar 02, 2021 (WiredRelease via Comtex) -- A recent systematic review report on “Anemia Drugs Market is Expected to Thrive at Impressive CAGR by 2031 |...
marketresearch.biz · 5d ago
Acceleron (XLRN) Q4 Loss Wider Than Expected, Revenues Beat
Zacks.com · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XLRN. Analyze the recent business situations of Acceleron through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XLRN stock price target is 145.42 with a high estimate of 173.00 and a low estimate of 101.00.
EPS
Institutional Holdings
Institutions: 377
Institutional Holdings: 56.24M
% Owned: 92.88%
Shares Outstanding: 60.55M
TypeInstitutionsShares
Increased
82
2.74M
New
69
935.70K
Decreased
84
3.51M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
Francois Nader
President/Chief Executive Officer/Director
Habib Dable
Chief Financial Officer/Senior Vice President/Treasurer
Kevin McLaughlin
Executive Vice President
Jay Backstrom
Executive Vice President
Sujay Kango
Senior Vice President/Chief Scientific Officer
Ravindra Kumar
Senior Vice President
Christopher R. Rovaldi
Director
Laura Hamill
Director
Christopher Hite
Independent Director
Terrence Kearney
Independent Director
Kemal Malik
Independent Director
Thomas McCourt
Independent Director
Karen Smith
Independent Director
Joseph Zakrzewski
No Data
About XLRN
Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Webull offers kinds of Acceleron Pharma Inc stock information, including NASDAQ:XLRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XLRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XLRN stock methods without spending real money on the virtual paper trading platform.